Abaloparatide vs Tesamorelin
Extensively Studied vs FDA Approved
synergistic Mechanism-based · 55% Abaloparatide and Tesamorelin work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
Abaloparatide Tesamorelin
Weight 3,960 Da 5,135.9 Da
Half-life ~1.7 hours 26-38 minutes
Chain 34 amino acids 44 amino acids
Type Synthetic PTHrP analog GHRH analog
Key Benefits
Abaloparatide
01 FDA-approved for osteoporosis treatment
02 Actively builds new bone (anabolic mechanism)
03 Superior hip BMD gains vs teriparatide in trials
04 Reduces vertebral fracture risk significantly
05 Reduces nonvertebral fracture risk
06 Lower hypercalcemia risk than teriparatide
07 Works through selective PTH1R activation
08 Benefits seen within 6 months
Tesamorelin
01 FDA-approved formulation
02 Selective visceral fat targeting (15-20% reduction)
03 Proven clinical efficacy
04 Standardized dosing
05 37% liver fat reduction in NAFLD
06 Preserved subcutaneous fat
Dosing Protocols
Abaloparatide
80 mcg / Once daily
Osteoporosis treatment 80 mcg Once daily
Tesamorelin
1.4-2mg daily (FDA-approved: 2mg for HIV lipodystrophy) / Once daily (evening preferred for GH rhythm)
HIV Lipodystrophy (FDA-approved) 1.4mg Once daily
Visceral Fat Reduction 2mg Once daily
Anti-aging/Body Composition 1-2mg 5-7x weekly
NAFLD Treatment 2mg Once daily (12 months)
Cognitive Enhancement 1mg Once daily (20 weeks)
Side Effects
Abaloparatide
Hypercalciuria (high calcium in urine)
Dizziness
Nausea
Headache
Palpitations
Fatigue
Upper abdominal pain
Vertigo
Injection site reactions
Tesamorelin
Injection site reactions (17%)
Joint pain (13%)
Water retention
Contraindications
Paget's disease of bone
Prior external beam or implant radiation therapy to skeleton
Bone metastases or history of skeletal malignancies
Metabolic bone diseases other than osteoporosis
Pre-existing hypercalcemia
Pregnancy or nursing
Cumulative use exceeding 2 years lifetime
Active malignancy
Pituitary disorders
Pregnancy
Research Evidence
Abaloparatide Tesamorelin
Status Extensively Studied FDA Approved
References 4 studies 5 studies
Latest — June 2025
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.